{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:01:39Z","timestamp":1789970499538,"version":"4.0.1"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Overexpression human epidermal growth factor receptor 2 (HER-2) has been identified as a key oncogenic driver in metastatic colorectal cancer (mCRC), detected in between 2% and 5% of the overall mCRC population, with a higher prevalence identified in RAS\/RAF\/PI3KCA wild-type patients. Optimal targeted interventions are seldom administered to patients with HER2-positive mCRC due to the absence of definitive anti-HER2 therapeutic regimens in the refractory setting. As a result, for patients who have undergone multiple lines of therapy\u2014particularly those with cetuximab resistance driven by ERBB2 amplification-mediated bypass activation\u2014treatment strategies are frequently confined to best palliative care or participation in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This report demonstrates a case of multi-line refractory mCRC with high-level HER2 overexpression. Following multi-line treatment therapies, the patient was treated with a zanidatamab-based chemotherapy salvage regimen, leading to a partial response (PR) and an ongoing progression-free survival of approximately 10 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case study highlights that the combination of zanidatamab with liposomal irinotecan and raltitrexed may provide an encouraging anti-tumor therapeutic option for mCRC patients with extremely high-level HER-2 overexpression and resistance to conventional anti-EGFR therapies. These findings offer valuable clinical insights into combining bispecific anti-HER2 targeted therapy with an optimized chemotherapy backbone, warranting further evaluation in prospective trials. Nevertheless, future prospective trials with larger cohorts are warranted to establish its survival benefits and universal applicability definitively.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1925069","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:59Z","timestamp":1789968959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: zanidatamab-based regimen as a potential later-line therapeutic option in HER2-amplified metastatic colorectal cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Lin","family":"Meng","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1186\/s12885-024-12831-4","article-title":"Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: aprospective open-label, single-arm, multi-center, phase II study","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal Irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(22)00621-0","article-title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","volume":"23","author":"Meric-Bernstam","year":"2022","journal-title":"Lancet Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1158\/1078-0432.CCR-24-2763","article-title":"ctDNA analysis in ERBB2-Amplified colorectal cancer: biomarker analysis of the MyPathway trial","volume":"31","author":"Meric-Bernstam","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-22-0283","article-title":"Molecular pathways and mechanisms of HER2 in cancer therapy","volume":"29","author":"Raghav","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ccell.2018.06.004","article-title":"Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer","volume":"34","author":"Siravegna","year":"2018","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1136\/gutjnl-2025-335412","article-title":"Current and emerging concepts for systemic treatment of metastatic colorectal cancer","volume":"74","author":"Steup","year":"2025","journal-title":"Gut"},{"key":"B16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.6004\/jnccn.2023.7022","article-title":"Real-world treatment patterns in patients with HER2-Amplified metastatic colorectal cancer: a clinical-genomic database study","volume":"21","author":"Strickler","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/14796694.2024.2441101","article-title":"MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer","volume":"21","author":"Strickler","year":"2025","journal-title":"Future Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41467-025-67824-z","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 +, RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis","volume":"17","author":"Strickler","year":"2026","journal-title":"Nat. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41467-023-37029-3","article-title":"An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity","volume":"14","author":"Weisser","year":"2023","journal-title":"Nat. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"99ra86","DOI":"10.1126\/scitranslmed.3002442","article-title":"Activation of ERBB2 signaling causes resistance to the EGFR-Directed therapeutic antibody cetuximab","volume":"3","author":"Yonesaka","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s13046-021-02130-2","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1925069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:35:59Z","timestamp":1789968959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1925069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":21,"alternative-id":["10.3389\/fphar.2026.1925069"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1925069","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1925069"}}